Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, including the patent system, and discusses ongoing legislative efforts to address ...

Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses how integrated delivery networks (IDNs) can help drive biosimilar adoption. Sophia Humphreys, ...

Blue Shield of California Lowers Humira Biosimilar Costs, Challenges PBM Pricing ...

The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products ...

Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous ...

Celltrion plans to commercialize 22 biosimilars by 2030, expanding its global presence with robust sales growth driven by ...

Direct costs associated with IBD include ambulatory visits to gastroenterologists, emergency department visits, admissions ...

On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, ...

On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, ...

An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and ...

By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster ...

Panelists emphasized the need for transparency and policy reforms in pharmacy benefit management (PBM) to improve ...